Alcon and ThromboGenics launch Jetrea in Canada

21 November 2013

Belgian biotech firm ThromboGenics NV (Euronext Brussels: THR) and its partner Alcon, the ophthalmic unit of Swiss drug major Novartis (NOVN: VX), have launched Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in Canada. Canada is the first market where Jetrea has been launched outside the USA and Europe.

Symptomatic VMA is estimated to affect up to 15,000 people in Canada each year. Health Canada approved Jetera in August following priority review. Alcon acquired the rights to commercialize Jetrea outside the USA in March 2012. The drug gained backing in the UK for National Health Service use earlier this year (The Pharma Letter June 12).

ThromboGenics is commercializing the drug in the USA and launched Jetrea in the USA in January where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK